# Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia

> **NCT00142181** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 27 (actual)

## Conditions studied

- Lymphoplasmacytic Lymphoma
- Waldenstrom's Macroglobulinemia

## Interventions

- **DRUG:** Campath-1H

## Key facts

- **NCT ID:** NCT00142181
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** 2005-10
- **Final completion:** 2008-06
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2012-12-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00142181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00142181, "Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00142181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*